Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentasa for Residual Immune Activation in Treated HIV
NCT03399903Phase 2Completed
- Sponsor
- AIDS Healthcare Foundation
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Salcrozine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by AIDS Healthcare Foundation. Primary endpoint: Inflammation markers at 14 weeks. Started May 2017; status: completed.
02
Drugs
Salcrozine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03399903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399903.